cyrilzakka/clinical-trials huggingface dataset:
An Evaluation of a Public Health Campaign Related to Persistent Pain in the United Kingdom

The goals of this study are

* To define what the public perceptions of persistent pain using a national survey
* Explore relationships between the reported pubic beliefs and demographic factors collected.
* To evaluate the impact of a public health campaign to increase awareness of persistent pain and develop understanding of pain that aligns with contemporary science.

This study included a cross sectional survey of the UK population to understand what the beliefs are regarding persistent pain. This survey will be distributed electronically using social media and to a Scottish council. Differences in beliefs will be explored using the demographic data collected.

The second aspect of the study is the evaluation of a public health campaign called 'Flippin Pain'. This study component included the evaluation of online webinars with pre, post, 3 month, 6 month and 12 month longitudinal data collection. One of the online seminars also included the qualitative evaluation using semi structured interviews.

The third part of the study was the evaluation of a community outreach tour in the county of Lincolnshire, United Kingdom. This included the collection of pain belief data before an in person seminar, immediately afterwards, then at 3 months. Semi structured interviews were also conducted with participants who attended the webinars. As part of the outreach tour an interactive pop up tent gave members of the public an understanding of pain using practical demonstrations. The was evaluated using short semi structured interviews along with written summaries offered by the participants before and immediately after experiencing the practical demonstrations.

After the community outreach tour, two focus groups were conducted with the campaign volunteers with an aim to understand the experience of those involved. The focus groups asked the participants to reflect on the successes and challenges of delivering a community based public health outreach tour.

Eligibility Criteria:
Inclusion Criteria:

* UK cross sectional survey - All adults over the age of 18 who are the capable of offering informed consent)
* Online webinar study - Adults over the age of 18 who attend an online webinar related to persistent pain
* Community outreach tour seminar - Adults over the age of 18 who attend an in person seminar
* Brain Bus - Adults over the age of 18 who experience the interactive demonstrations relating to persistent pain
* Focus Groups - Volunteers who participated in the Flippin Pain community outreach tour within the county of Lincolnshire

Exclusion Criteria:

* Individuals younger than 18 years of age.
* For the cross sectional UK survey, adults who lived outside of the UK were excluded.
Pattern and Management of Intracranial Cavernoma

Intracranial cavernous vascular malformations are variously known as cavernous angiomas, cavernous hemangiomas, or, more simply, cavernomas. Cavernomas are congenital low flow vascular lesions. It composed of irregular sinusoidal vascular channels, lacking smooth muscle, and elastic fibers. They lack feeding arteries or draining veins and contain no neural tissue. The first description of an intracranial cavernoma was given by Virchow, in 1863. For over a century, it was considered to be an extremely rare malformation, usually found at autopsy, and exceptionally diagnosed during life. The prevalence of cerebral cavernous malformations (CCM) is estimated to be 0.4-0.9%.


Eligibility Criteria:
Inclusion Criteria:

* All patients presented with intracranial cavernomas (single or multiple, superficial or deep, supratentorial or infratentorial)
* Denovo or recurrent patients.

Exclusion Criteria:

* None
Small Bowel Motor Impairment in Scleroderma: Results of a Prospective 5-year Manometric Follow-up

Small bowel involvement is still recognized to be associated with great morbidity and mortality in SSc patients, leading particularly to malabsorption and intestinal pseudo-obstruction. Intestinal disorders directly related to SSc have, in fact, been reported to be one of the most common causes of death.

In a previous prospective study, we have demonstrated the high prevalence of small intestinal involvement in SSc patients, using upper intestinal manometry; in turn, 88% of our SSc patients had upper intestinal motor disturbances. However, to date, no authors have yet analyzed the course of upper intestinal motor dysfunction in SSc.

The aims of this study were therefore to assess the 5-year course of small bowel motor disorders, using manometry in patients with systemic sclerosis (SSc), and to investigate for an association between upper intestinal motor dysfunction outcome and other clinical manifestations of SSc.


Eligibility Criteria:
Inclusion Criteria:

* patients with systemic sclerosis, who had an upper intestinal tract manometry 5 years before, with:

  * age over 18 years
  * written informed consent

Exclusion Criteria:

* pregant women
* patients with psychiatric conditions
* unwritten informed consent
Assessment of LV/RV S and SR Before and After Percutaneous Closure of ASDs

The effect of Atrial Septal Defect (ASD) closure by using larger devices on the improvement in biventricular function remains an area of active research. Therefore, the aim of the current study is to assess the degree of improvement in biventricular dimensions and function by using 2-Dimensional echocardiography derived Strain and Strain Rate and Tissue Doppler. Moreover, to identify the relationship between the left and right ventricular systolic and diastolic function and device size.

In most echocardiographic studies, left ventricle (LV) systolic function was normal in the patients with ASD and only a few cases had a reduced LV ejection fraction with severe right ventricle (RV) volume overload. The device closure of ASD increases immediately the blood flow to the left ventricle and may unmask subtle abnormalities in systolic and diastolic function. Currently, clinical research in cardiac mechanics is moving from short- and long-axis LV and RV function and ejection fraction to two and three- dimensional (2D, 3D) ventricular deformation studies (Strain and Strain Rate quantiﬁcation). These methods are independent of ventricular geometry and allow quantiﬁcation of myocardial motion and deformation in different directions (longitudinal, radial, and circumferential), while conventional methods mainly rely on the assessment of radial function. Strain imaging has also been used to demonstrate that patients who underwent device closure of an ASD had better LV and RV longitudinal deformation than patients who underwent surgical closure of an ASD. However, the effect of device size on the LV systolic and diastolic function is still under investigations. For all these reasons the researchers intend to measure RV and LV haemodynamic changes by 2-D Transthoracic Echocardiography (TTE) derived Tissue Doppler and Strain quantification in ASD before and after transcatheter closure with special emphasis on the assessment of the relationship between device size and biventricular systolic and LV diastolic function.

Eligibility Criteria:
Inclusion Criteria:

* All ASD patients who have been already selected and suitable for intervention before the starting time of the study. The criteria for ASD intervention are either haemodynamically significant shunt fraction (Qp/Qs \> 1.5) or echocardiographic signs of right heart dilation or RV volume overload and pulmonary hypertension related symptoms.

Exclusion Criteria:

* Patients with a large stretched Secundum ASD ≥ 36 mm, those with insufficient ASD rims (except the aortic rim), sinus venosus or primum type ASD, irreversible pulmonary hypertension, other associated structural heart diseases, coronary artery disease, LV systolic dysfunction, atrial fibrillation, or hypertension.
Treatment of Patients With Neck Pain After a Commuting Accident

Introduction. Neck pain is one of the main causes of incapacity for work. The economic impact of neck pain is considerable due to the cost of medical treatment and physiotherapy. Accidents in itinere, those that occur on the way between home and the workplace, can cause pain and functional impairment.

Objective. To analyze the relationship between the time off work following accidents on the way to and from work and the type of treatment received.

Material and method. Multicenter retrospective cohort study. Data will be collected from 146 patients. The primary variable of the study will be the time on sick leave (in days), with the type of intervention received (manual therapy or not) being the dependent variable. The secondary variables, estimated as modifying or confounding, will be the intensity of the pain (visual analog scale), sex, age, occupational cervical strain, type of contract (salaried/self-employed) and the number of physiotherapy sessions received.


Eligibility Criteria:
Inclusion Criteria:

* Patients of both sexes
* Persons aged 18 to 65
* Patients with a medical diagnosis of neck pain secondary to traffic accidents while commuting
* Persons without a medical diagnosis of another associated pathology
* Patients whose accident occurred between 2022 and 2024.

Exclusion Criteria:

* Patients who have received physiotherapy treatment at another centre during the process
* Patients who requested voluntary discharge for whatever reason.
Effect of Dialysate Cooling Versus Sodium Profiling in Management of Intradialytic Hypotension Among Chronic Hemodialysis Patients

Chronic kidney disease (CKD) is a worldwide public health issue. Dialysis patients have a tenfold greater relative risk of cardiovascular death than the general population.

Dialysate cooling prevents intradialytic hypotension (IDH). This is achieved by inducing vasoconstriction and activating the sympathetic nervous and therefore improving hemodynamic stability .

Intradialytic hypotension (IDH) is a common complication of HD. There is no consensus on the definition of IDH, but (IDH) is commonly defined as a drop in blood pressure during dialysis procedure and/ or hypotensive symptoms such as dizziness, weakness, nausea, cramps, blurred vision, and fatigue .

The pathophysiology of IDH is diverse. It could be the result of an inadequate cardiovascular response to the reduction in blood volume that occurs when the ultrafiltration volume is large . One process may involve an imbalance between a reduced effective circulating volume and the compensatory plasma refilling mechanism, wherein fluid from the interstitial and intracellular space is translocated into the intravascular compartment .

Cold dialysis reduces HD-induced brain damage by protecting the cerebral vascular beds from harmful perfusion . In the heart, long- term cold dialysis improved resting ejection fraction and reduced left ventricular mass and end-diastolic volumes while preserving aortic distensibility, decreasing the risk for future cardiovascular events

. Risk factors associated with IDH include old age, female gender, Hispanic ethnicity, long dialysis vintage, high intradialytic weight gain, high dialysis dose, anemia, diabetes, low pre-dialysis BP, high osmolarity, and high body mass index .

It can be applied universally and reduce the need for nursing involvement . Further, no additional cost is needed to conduct fixed reduction of dialysate temperature. While there are various methods of reducing dialysate temperature, optimal temperature or methods of temperature reduction to prevent IDH remain uncertain

To study the effect of dialysate cooling (0.5- 1 C lower than pre- dialysis core body temperature) Vs traditional sodium profiling on:

1. Reduction the episodes of IDH .
2. Net dry weight achievements.
3. Post dialysis fatigue.


Eligibility Criteria:
Inclusion Criteria:

* • Patients age 18-70 years old.

  * Maintained on HD for not less than 6 months
  * Documented episodes of IDH

Exclusion Criteria:

* • Severly anemic patients (Hb\<7 g/dl)

  * Patients taking more than 3 antihypertensive (on days other than dialysis day).
  * Patients with documented IHD.
  * Patients on midodraine therapy prior dialysis session.
  * patient refusal, incompliance or ineffective dialysis.
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

This study was designed to evaluate the effectiveness of Anlotinib in middle-advanced Hepatocellular Carcinoma (HCC) Patients.

The aim of this study is to include 40 patients with middle-advanced Hepatocellular Carcinoma .These patients were randomly allocated to TACE treatment group or TACE+Anlotinib treatment group.The treatment effectiveness, local tumor control and survival outcome between the two groups were compared.

Eligibility Criteria:
Inclusion Criteria:

1. Subject has no contraindication to chemotherapy, and has no obvious obstacles in the function of major organs such as heart, lung, liver and kidney;
2. Subject has middle-advanced liver cancer of Barcelona Clinic Liver Cancer stages B/C ;
3. Liver function child-pugh class A or B; Karnofsky (KPS) score \> 60 points;
4. Subject could not accept surgical resection or refuse surgical operation;and who did not receive other treatment before operation.

5.18\~75 years old; ECOG PS score: 0-1 points; expected survival period is more than 3 months.

Exclusion Criteria:

1. Subject has contraindications to chemotherapy;
2. Subject has obstacle in the function of major organs such as heart, lung, liver and kidney;
3. Severe coagulation dysfunction (prothrombin time \> 18 s or hemorrhagic tendency);
4. Uncontrollable hypertension and portal hypertension;
5. Hepatic artery-portal vein or hepatic vein fistula or portal vein trunk cancer thrombus;
6. A large amount of ascites or refractory ascites;
7. With distant metastasis.
The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals

The objective of this national and multidisciplinary project is to establish and evaluate a personalized surveillance program (SP) for early diagnosis of pancreatic cancer (PC) and its precursors in individuals with a hereditary predisposition to the disease (High RIsk Individuals (HRI)). Patients who either carry a germline mutation in a PC susceptibility gene (CDKN2A, STK11, TP53, PRSS1), or have a strong family history of PC, will be enrolled through their genetics clinic at the university hospitals in Oslo, Bergen, Trondheim and Tromsø. Surveillance consists of annual MRI, assessment of blood glucose and lipid levels, new onset diabetes (NOD) and unintentional weight loss. Blood samples will be drawn for ctDNA-analysis (circulating tumor DNA) and the IMMrayTM PanCan-d test (a novel microarray-based diagnostic test for PC) at baseline and in those who develop lesions. The psychological burden and cost-benefit of the SP will be analyzed. The study addresses an unmet need for the care of HRI in Norway, and is expected to improve PC prognosis. It will be the first to provide evidence on the combined value of a panel of blood-borne biomarkers in surveillance, and provide morphological and molecular data on PC and (non)-neoplastic pancreatic changes in HRI.


Eligibility Criteria:
Inclusion Criteria:

1. Men or women with a germline mutation in CDKN2A, TP53, PRSS1 or STK11
2. Men or women who are first degree relatives to a patient with pancreatic cancer (PC) in a family with Familial Pancreatic Cancer (FPC).

Exclusion Criteria: Patients undergoing active cancer treatment.
PIE II: Pharmacological Intervention in the Elderly II

The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).

Exercise intolerance due to HFPEF is a major cause of disability among older Americans. Several lines of evidence suggest that aldosterone antagonism may improve exercise tolerance in HFPEF. Therefore, the primary aim of this study is to test the hypothesis that spironolactone will improve exercise tolerance and quality of life in elderly patients with isolated HFPEF. A total of 72 participants aged 60 or older will be randomized to receive either spironolactone 25mg daily or a placebo.

Eligibility Criteria:
Inclusion Criteria:

* Ambulatory
* Medically stable
* Ages 60 or older
* Diagnosis of diastolic heart failure

Exclusion Criteria:

* Valvular heart disease
* Significant change in cardiac medication within the past 4 weeks
* Uncontrolled hypertension
* Recent or debilitating stroke
* Cancer or other noncardiovascular conditions with life expectancy less than 2 years
* Anemia
* Elevated serum potassium
* Renal insufficiency
* Psychiatric disease (uncontrolled major psychoses, depression, dementia, or personality disorder)
* Allergy to spironolactone; currently taking spironolactone or any aldosterone antagonist
* Plans to leave area within 1 year
* Refuses informed consent
* Failure to pass screening tests: pulmonary function, echocardiogram, or exercise
* Contra-indications to magnetic resonance imaging \[MRI\] (indwelling metal-containing prosthesis; pacemaker or defibrillator; history of welding occupation; uncontrollable claustrophobia)
Effects of Supplementation With Amino Essential Acids on Circulating Albumin Levels in Stroke in Rehabilitation Phase

In addition to its physiological functions, serum albumin plays a role of neuroprotection in cerebrovascular stroke. The circulating levels of albumin may be reduced in patients with stroke due to the presence of a systemic inflammatory state and to the inadequacy of protein-energy intake. The circulating levels of albumin have proven to be predictors of functional recovery in ischemic stroke and cerebral hemorrhage.

In the present survey it is hypothesized that it is possible to significantly improve the values of hypoalbuminemia by supplementation with essential amino acids and that, in the second place, any increase in albumin may result in a strengthening of functional recovery in patients with a stroke.

In addition to its physiological functions, serum albumin plays a role of neuroprotection in cerebrovascular stroke. The circulating levels of albumin may be reduced in patients with stroke due to the presence of a systemic inflammatory state and to the inadequacy of protein-energy intake. In the patients admitted to the Montescano Neuromotor Rehabilitation Division, the prevalence of hypoalbuminemia is high at the time of admission and remains high, even if decreased, at discharge. The circulating levels of albumin have proven to be predictors of functional recovery in ischemic stroke and cerebral hemorrhage. In the present survey it is hypothesized that it is possible to significantly improve the values of hypoalbuminemia by supplementation with essential amino acids and that, in the second place, any increase in albumin may result in a strengthening of functional recovery in patients with a stroke.

Several factors induce the use of free essential amino acids: they are the most efficient inducers of protein synthesis and albumin is a protein; free essential amino acids and not those contained in proteins allow a more reliable use of the isoleucine and tryptophan, true nutrients limiting the hepatic synthesis of albumin; the free essential amino acids have a faster and complete intestinal absorption of the essential amino acids derived from protein digestion.

Eligibility Criteria:
Inclusion Criteria:

* first episode of cerebral stroke
* first taken in rehabilitation after hospitalization in the acute department

Exclusion Criteria:

* neoplasia
* long-term corticosteroid therapy (\> 3 weeks) in the pre-event period and at the time of admission to the rehabilitation department
Effect of Oral Sildenafil With Digital Therapeutic Iontophoresis of Sodium Nitroprussiate in Healthy Volunteers

Iontophoresis is a employed to facilitate drug absorption without systemic effect. This study investigates cutaneous microcirculation when we associate sildenafil per os with SNP via iontophoresis.

The main outcome is the proof of concept of effect of systemic absorption sildenafil on cutaneous microcirculation associated with SNP iontophoresis.

Eligibility Criteria:
Inclusion Criteria:

* Age over 18
* No significant medical history

Exclusion Criteria:

* Age under 18
* Period of exclusion for an other study
* Pregnancy
* Breast feeding
* Severe disease
* Cigarette smoking
Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients

To demonstrate the effects of Lucentis (ranibizumab), Avastin ( bevacizumab), and Eylea ( aflibercept) on the levels of naturally occurring Vascular Endothelial Growth Factor (VEGF) in the systemic circulation of Age Related Macular Degeneration patients currently treated with these medications.

To determine plasma levels of VEGF and serum Pharmacokinetic (PK) levels after varying lengths of time following intravitreal injection with Avastin, Lucentis, or Eylea in exudative macular degeneration. Patients will be tested while following a normal course of treatment in our institute. All screenings and testing will be conducted in three study visits.

Eligibility Criteria:
Inclusion Criteria:

1. Ability to provide written informed consent for participation in this study.
2. Adults ≥ 50 years of age with exudative macular degeneration treated with Avastin, Lucentis, or Eylea in previously determined time intervals exclusive to a single anti-VEGF treatment type for not than three months.
3. CONTROL GROUP: Age matched control group with no previously diagnosed exudative macular degeneration will also be enrolled.
4. Provide signed informed consent.

Exclusion Criteria:

1. Uncontrolled blood pressure (defined as systolic \> 160mm Hg or Diastolic \> 95mm Hg while patient is sitting)
2. Uncontrolled diabetes mellitus defined by Hemoglobin A1c (HbA1C \> 12% at screening)
3. Concomitant ocular or systemic administration of drugs that may interfere with or potentiate the mechanism of action of anti-VEGF medications.
4. Previous administration of systemic anti-angiogenic medications within 3 months
5. Participation in a simultaneous medical investigation or trial.
6. Treatment within 2 months with anti-VEGF agent in the fellow eye or anticipated need for further treatment during the study.
7. Patients with any cancer diagnosis in remission for less than five years with the exception that patients with skin cancers, basal cell or squamous cell, treated exclusively or topical treatment will be allowed.
8. Female patients who have not reached menopause, defined as cessation of menses for a minimum of twelve months with no perimenopausal symptoms.
9. Patients who have significant wound healing during the trial.
10. Patients with a history of vitrectomy in the study eye.
11. patients with uncontrolled psoriasis, rheumatoid arthritis, osteoarthritis.